Expected Moves

Genfit is scheduled to provide a comprehensive pipeline update outlining the finalized Phase 2 clinical designs for its ACLF (NTZ) and CCA (GNS561) programs.

Publication of revenue and cash position as of September 30, 2026, offering a direct read-through on Q3 Iqirvo prescription volumes and milestone triggers.

Expected commencement of the Phase 2 clinical trial for GNS561 in combination therapy for heavily pretreated KRAS-mutated cholangiocarcinoma.

The end-of-year deadline for Iqirvo to achieve a pre-defined 2026 net sales threshold, which unlocks a €25 million third installment under Genfit's royalty financing agreement with HCRx.

Annual financial results reporting total 2026 royalty inflows from Ipsen, MASH diagnostics revenue progression, and 2027 cash runway projections.

Presentations at the European Association for the Study of the Liver (EASL) Congress, potentially featuring early metrics for the NTZ Phase 2 trial in Acute on-chronic Liver Failure.

Market reassessment of Iqirvo's forward revenue curve as competing PBC therapies mature in the second-line treatment landscape.